Popular Articles

Shire Presented Results Of A New Database Analysis On Lialda(R) (Mesalamine) And Other 5-ASAs For Ulcerative Colitis At Digestive Disease Week
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Large Pharmacy Database," at Digestive Disease Week, on May 31, 2009. Results showed that after 12 months of therapy for continuing patients, 20 percent of Lialda patients were continually persistent, 9 percent of Asacol(R) (mesalamine) patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa(R) (mesalamine) patients, 10 percent of balsalazide [combined results from generic balsalazide disodium and Colazal(R) (balsalazide disodium)] patients, and 10 percent (500mg) of Dipentum(R) (olsalazine sodium) patients were persistent. Continually persistent patients were defined as those who refilled their prescription within a period of up to twice the duration of the prescription that preceded the refill. Lialda is an FDA-approved, once-daily oral medication for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC). Safety and effectiveness of Lialda beyond eight weeks have not been established. Buy arimidex to treat cancer.

ATS Medical Announces Participation In The International Society For Minimally Invasive Cardiothoracic Surgery Meeting
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced participation in the upcoming International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Meeting in San Francisco on June 3-6, 2009. The ISMICS meeting is a significant gathering of cardiovascular surgeons from around the world whose interests include the latest developments in less invasive forms of heart surgery. The annual ISMICS meeting provides an excellent venue for the Company to exhibit its growing portfolio of clinically relevant products designed to meet the needs of cardiac surgeons.

generic viagra online


News of the day
Less Frequent Social Activity Linked To More Rapid Loss Of Motor Function In Older Adults
Loss of muscle strength, speed and dexterity is a common consequence of aging and a well-established risk factor for death, disability and dementia. Yet little is known about how and why motor decline occurs when it is not a symptom of disease.
Nutrition

Potential For Noninvasive Brain Tumor Treatment

Duke University engineers have taken a first step toward a minimally invasive treatment of brain tumors by combining chemotherapy with heat administered from the end of a catheter. The proof-of-concept study demonstrated that it should be technically possible to treat brain tumors without the side effects associated with the traditional approaches of surgery, systemic chemotherapy or radiation. The bioengineers designed and built an ultrasound catheter that can fit into large blood vessels of the brain and perform two essential functions: provide real-time moving 3-D images and generate localized temperature increases. The researchers envision using this system in conjunction with chemotherapy drugs encased in heat-sensitive microbubbles called liposomes. "Physicians would inject drug-carrying liposomes into a patient"s bloodstream, and then insert a catheter via a blood vessel to the site of the brain tumor," said Carl Herickhoff, fourth-year graduate student at Duke"s Pratt School of Engineering and first author of a paper appearing in the journal Ultrasonic Imaging. "The catheter would use ultrasound to first image the tumor, and then direct a higher-power beam to generate heat at the site, melting the liposome shells and releasing the chemotherapy directly to the tumor. "The temperature increase would be about four degrees Celsius - enough to melt the liposome, but not enough to damage surrounding tissue," Herickhoff said. "No one has tried this approach before in the brain." The American Cancer Society estimates that more than 21,000 new brain tumor cases were diagnosed in 2008, with more than 13,000 patients dying. This represents about two percent of all cancer deaths. The researchers said that a minimally invasive approach to treating this cancer would be preferable to the conventional methods, which have drawbacks and side effects of their own. "Surgery is invasive, and chemotherapy that is injected or taken orally affects the whole body and has difficulty crossing the blood-brain barrier in sufficient concentrations," Herickhoff said. The blood-brain barrier restricts the passage into the brain of any foreign matter not needed by the neural tissue. In a series of experiments in animal models and simulated tissues, the researchers demonstrated that they could build a catheter thin enough to be placed in one of the brain"s main blood vessels that was capable of serving the dual purpose of visualization and heating. "Taken as a whole, the results of these experiments, in particular the clarity of the images and ability to increase temperature with the same catheter, lead us to believe that the ultimate creation of a practical intracranial ultrasound catheter is possible," said Stephen Smith, director of the Duke University Ultrasound Transducer Group and senior member of the research team. "There are some design issues of the catheter itself that we feel can be overcome with little difficulty." Advances in ultrasound technology have made these latest experiments possible, the researchers said, by generating detailed, 3-D moving images in real-time. The Duke laboratory has a long track record of modifying traditional 2-D ultrasound - like that used to image babies in utero - into the more advanced 3-D scans. After inventing the technique in 1991, the team also has shown its utility in developing specialized catheters and endoscopes for real-time imaging of tissues throughout the body. Much of the liposome research was carried out at Duke by David Needham, professor of mechanical engineering and materials science, and Mark Dewhirst, professor of radiation oncology. The research in Smith"s lab is supported by the National Institutes of Health. Other members of the team, also from Duke, are Edward Light, Kristin Bing, Srinivasan Mukundan, Gerald Grant and Patrick Wolf. Richard Merritt Duke University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):